Skip to Content

'
Nicholas E. Papadopoulos, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard,
Unit Number: 430
Houston,, TX 77030
Phone: 713 792-2921
Fax: 713 745-1046

Education & Training

Degree-Granting Education

1966 University of Athens, Athens, Greece, MD, Medicine

Postgraduate Training

1976-1978 Fellow in Medicine, Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX
1974-1976 Residency, Medicine, Baylor College of Medicine, Houston, TX

Selected Publications

Peer-Reviewed Original Research Articles
1. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma. Cancer Invest 27(7):756-63, 8/2009. PMID: 19440934.
2. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8). e-Pub 8/2009. PMID: 19671763.
3. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19(4):238-42, 8/2009. PMID: 19521262.
4. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol 64(1):167-7, 6/2009. e-Pub 11/2008. PMID: 19002462.
5. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. Am J Clin Oncol. e-Pub 6/2009. PMID: 19506454.
6. Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, Arellano ML. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32(3):322-4, 4/2009. PMID: 19242368.
7. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-9, 2/2009. PMID: 19430405.
8. Bedikian AY, Papadopoulos NE, Kim KB, Vardeleon A, Smith T, Lu B, Deitcher SR. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 18(6):400-4, 12/2008. PMID: 19011511.
9. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-8, 12/2008. PMID: 18798304.
10. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Brit J Cancer 99(5). e-Pub 8/2008. PMID: 18728664.
11. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26(6):624-33, 7/2008. PMID: 18584354.
12. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 101:596-603, 8/2004. PMID: 15274073.
13. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100:1478-83, 4/2004. PMID: 15042682.
14. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 14:63-6, 2/2004. PMID: 15091196.
15. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98:2693-9, 12/2003. PMID: 14669291.
16. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21:3158-67, 8/2003. PMID: 12915607.
17. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 13:303-6, 6/2003. PMID: 12777987.
18. Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97:2848-52, 6/2003. PMID: 12767099.

Abstracts
1. Kim, KB, Hodges C, Papadopoulos N, Eton O, Camacho LH, Ballo MT, Bedikian AY. Biochemotherapy in patients with metastatic anorectal melanoma (MAM). . Proc. Am Soc Clin Oncol 22:718 (#2889), 2003.
2. Papadopoulos, N, Bedikian AY, Ring S, Kim KB, Camacho LH, Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). . Proc. Am Soc Clin Oncol 22:718, 2003.

Last updated: 9/23/2009